Home Coronavirus COVID-19 ‘Vaccines’ are Gene Therapy

COVID-19 ‘Vaccines’ are Gene Therapy

by Paul Ebeling

#COVID19 #vaccine #gene #therapy

Safety data analysis and reporting in clinical trials of the COVID jabs appear to have been manipulated in at least some cases.

A Key method for manipulating randomized clinical trial safety data is to only analyze the “per protocol” treatment group, those who completed all doses and were fully compliant with the study design as opposed to “intent to treat” which would include all patients that have signed informed consent

For example, if a participant only accepted 1 dose and trial protocol called for 2, under a “per protocol” analysis, adverse events they experienced would be dismissed and not included in the safety analysis. This is a classic way to manipulate safety data in clinical research, and it’s usually forbidden

Since the COVID shots only have emergency use authorization, they are experimental products and, as such, are not authorized for marketing

Bioethics are written into federal law.

As an experimental trial participant, you have the right to receive full disclosure of any adverse event risks. Full disclosure of risks is not being done, and in fact is being suppressed

Adverse event risks must also be communicated in a way that you can comprehend what the risks are, and the acceptance of an experimental product must be fully voluntary and uncoerced. Enticement is strictly forbidden!

Have a healthy weekend, Keep the Faith!

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2023 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.